EUVIMEDEUVIMED entdecken
Crossref

Disparities in Prescription of Long‐Acting GLP‐1s

Katherine Wasden iD, Nora Sheu, Pourya Medhati, Thomas C Tsai, Dong Wook Kim, Ali Tavakkoli, Caroline M Apovian iD, Eric G Sheu

Obesity · 2026

DOI: 10.1002/oby.70152 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Obesity, 2026. Verfasst von Katherine Wasden und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory for Surgical and Metabolic Research, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Glucagon-Like Peptide 1, Obesity, Healthcare Disparities, Anti-Obesity Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Broadening usage of new antiobesity medications (AOMs, e.g., GLP‐1 and GLP‐1/GIP agonists) has prompted access concerns. We analyzed patient and appointment factors associated with AOM prescriptions, including changing AOM coverage in state Medicaid programs (MassHealth).

Methods

This was a retrospective pre‐post study of medical weight management appointments at a large tertiary care center in January and April 2024, bracketing a MassHealth coverage change for AOMs. Patient and visit characteristics and AOMs prescribed were analyzed.

Results

A total of 2060 patients were analyzed. Multivariable analysis demonstrated that patients were more likely to receive Sema/Tirz compared to no or a different AOM with private insurance (aOR 2.744, p < 0.001), diabetes (aOR 2.507, p < 0.001), and established patient relationships (aOR 1.706, p < 0.001). In January 2024, Black and Hispanic patients were 49% and 47% less likely to be prescribed Sema/Tirz ( p = 0.003, p = 0.025); in April 2024, after MassHealth changes, only patients of “Not Disclosed” race were less likely to receive these medications ( p < 0.001).

Conclusions

Black and Hispanic patients were less likely and patients with private insurance, diabetes, and established patient relationships were more likely to be prescribed Sema/Tirz. Racial and ethnic disparities in medication prescription were less apparent after a state Medicaid policy change to cover new GLP‐1s.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide 1ObesityHealthcare DisparitiesAnti-Obesity AgentsDrug PrescriptionsHumansRetrospective StudiesFemaleUnited StatesMedicaidMaleMiddle AgedAdultHispanic or LatinoBlack or African American

Stichwörter der Autor:innen

disparityinsurancelong‐acting GLP‐1obesityobesity medications

Substanzen

Glucagon-Like Peptide 1Anti-Obesity Agents

Autor:innen und Institutionen

  • Laboratory for Surgical and Metabolic Research, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Division of General and Gastrointestinal Surgery, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Center for Weight Management and Wellness, Brigham and Women's Hospital, Boston, Massachusetts, USA.

ORCID-Profile: Katherine Wasden, Caroline M Apovian

Zitieren

APA

Wasden, K., Sheu, N., Medhati, P., Tsai, T. C., Kim, D. W., Tavakkoli, A., Apovian, C. M., & Sheu, E. G. (2026). Disparities in Prescription of Long‐Acting GLP‐1s. Obesity. https://doi.org/10.1002/oby.70152

Vancouver

Wasden K, Sheu N, Medhati P, Tsai TC, Kim DW, Tavakkoli A, et al. Disparities in Prescription of Long‐Acting GLP‐1s. Obesity. 2026. doi:10.1002/oby.70152

BibTeX
@article{Wasden2026,
  author = {Wasden, Katherine and Sheu, Nora and Medhati, Pourya and Tsai, Thomas C and Kim, Dong Wook and Tavakkoli, Ali and Apovian, Caroline M and Sheu, Eric G},
  title = {Disparities in Prescription of Long‐Acting GLP‐1s},
  journal = {Obesity},
  year = {2026},
  doi = {10.1002/oby.70152}
}
Kostenlos starten →